ACTG 239--PHASE I/II TO EVALUATE CD4 DECLINE AND GROWTH IN INFANTS WITH HIV

ACTG 239——评估 HIV 感染婴儿 CD4 下降和生长的 I/II 期

• 批准号: 6274983
• 负责人: FRANK GIGLIOTTI
• 金额: $ 1.96万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274983
• 关键词: 2'3' dideoxyinosine; AIDS therapy; CD4 molecule; HIV infections; antiAIDS agent; child physical development; clinical research; clinical trials; combination chemotherapy; disease /disorder proneness /risk; helper T lymphocyte; human subject; human therapy evaluation; infant human (0-1 year); pathologic process; pediatric AIDS; zidovudine

This is a two-part, ... study of ZDV alone versus the combination of ZDV and ddi for the treatment of infants less than or equal to 90 days of age or less than or equal to 120 days of age who have symptomatic HIV infection or are at risk for rapid disease progression.

这是一个两部分，…ZDV单独与ZDV组合的研究 和DDI用于治疗小于或等于90日龄的婴儿 或小于或等于120日龄的有症状的艾滋病毒感染者 感染或处于疾病快速进展的风险中。